BIOMARIN PHAR. DL-,001 | 67.95 / 0.00% |
Date/Time | 01/16 / 12:37 |
Chg. / Chg.(%) | 0.00 / 0.00% |
Bid | 67.95 |
Ask | 68.78 |
Open | 67.95 |
Previous Close | 67.95 |
High | 67.95 |
Low | 67.95 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 8 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Lang & Schwarz |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 67.95 | ![]() |
|
NASDAQ | 82.9700 | ![]() |
1,306,558 |
Cboe US | 82.85 | ![]() |
89,343 |
IEX | 82.89 | ![]() |
62,135 |
TradeGate | 68.200 | ![]() |
988 |
Vienna Globa.. | 68.08 | ![]() |
849 |
gettex | 69.110 | ![]() |
70 |
Frankfurt | 67.7500 | ![]() |
64 |
Xetra | 68.08 | ![]() |
0 |
Berlin | 66.75 | ![]() |
0 |
München | 67.07 | ![]() |
0 |
Düsseldorf | 68.45 | ![]() |
0 |
Stuttgart | 68.800 | ![]() |
0 |
Mexico | 1,599.31 | ![]() |
4,200 |
London Inter.. | 81.84 | 295 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire